Fulcrum Therapeutics (NASDAQ:FULC) Announces Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Fulcrum Therapeutics (NASDAQ:FULC) issued its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03), Zacks reports.

Fulcrum Therapeutics Stock Performance

Shares of FULC stock opened at $3.70 on Wednesday. Fulcrum Therapeutics has a 12-month low of $2.86 and a 12-month high of $13.70. The company has a market cap of $199.57 million, a price-to-earnings ratio of -11.94 and a beta of 2.03. The stock has a 50 day simple moving average of $4.15 and a 200-day simple moving average of $4.62.

Analysts Set New Price Targets

A number of brokerages have recently commented on FULC. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.